ATE402697T1 - 1,3,5-trisubstituierte 4,5-dihydro-1h-pyrazol- derivative mit cb1-antagonistischer aktivität - Google Patents

1,3,5-trisubstituierte 4,5-dihydro-1h-pyrazol- derivative mit cb1-antagonistischer aktivität

Info

Publication number: ATE402697T1
Authority: AT; Austria
Prior art keywords: trisubstituted; dihydro; antagonistic activity; pyrazole derivative; compounds
Prior art date: 2004-01-30

Application number

AT05707857T

Other languages

English (en)

Inventor

Josephus Lange

Cornelis Kruse

Stuivenberg Herman Van

Original Assignee

Solvay Pharm Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-01-30

Filing date

2005-01-27

Publication date

2008-08-15

2005-01-27 Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv

2008-08-15 Application granted granted Critical

2008-08-15 Publication of ATE402697T1 publication Critical patent/ATE402697T1/de

Links

-1 1,3,5-TRISUBSTITUTED 4,5-DIHYDRO-1H-PYRAZOLE Chemical class 0.000 title abstract 2
230000003042 antagnostic effect Effects 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
229940124802 CB1 antagonist Drugs 0.000 abstract 1
230000009286 beneficial effect Effects 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
150000003217 pyrazoles Chemical class 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Obesity (AREA)
Oncology (AREA)
Physical Education & Sports Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Gastroenterology & Hepatology (AREA)
Virology (AREA)
Addiction (AREA)
Psychology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)

AT05707857T 2004-01-30 2005-01-27 1,3,5-trisubstituierte 4,5-dihydro-1h-pyrazol- derivative mit cb1-antagonistischer aktivität ATE402697T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US53998304P	2004-01-30	2004-01-30
EP04100338		2004-01-30

Publications (1)

Publication Number	Publication Date
ATE402697T1 true ATE402697T1 (de)	2008-08-15

Family

ID=34839806

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05707857T ATE402697T1 (de)	2004-01-30	2005-01-27	1,3,5-trisubstituierte 4,5-dihydro-1h-pyrazol- derivative mit cb1-antagonistischer aktivität

Country Status (20)

Country	Link
EP (1)	EP1713475B1 (de)
JP (1)	JP4693787B2 (de)
KR (1)	KR20060131861A (de)
CN (1)	CN100563651C (de)
AT (1)	ATE402697T1 (de)
AU (1)	AU2005210163B2 (de)
BR (1)	BRPI0507005A (de)
CA (1)	CA2552940A1 (de)
DE (1)	DE602005008555D1 (de)
DK (1)	DK1713475T3 (de)
ES (1)	ES2311972T3 (de)
HR (1)	HRP20080549T3 (de)
IL (1)	IL176547A (de)
MX (1)	MXPA06008593A (de)
NO (1)	NO20063866L (de)
PL (1)	PL1713475T3 (de)
PT (1)	PT1713475E (de)
RU (1)	RU2360904C2 (de)
SI (1)	SI1713475T1 (de)
WO (1)	WO2005074920A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200533657A (en) *	2004-02-17	2005-10-16	Esteve Labor Dr	Substituted pyrazoline compounds, their preparation and use as medicaments
ES2348374B1 (es) *	2005-07-15	2011-08-02	Laboratorios Del Dr Esteve, S.A.	Formulaciones farmaceuticas orales que comprenden compuestos de pirazolina sustituidos.
ES2330993B1 (es) *	2005-07-15	2010-07-06	Laboratorios Del Dr. Esteve, S.A.	Combinacion de antagonista del receptor de cannabinoides de tipo pirazolina y estatina.
EP1745781A1 (de) *	2005-07-15	2007-01-24	Laboratorios Del Dr. Esteve, S.A.	Kombination von Cannabinoid Rezeptor Antagonist des Pyrazolin-Typs und Statin
WO2007009705A1 (en) *	2005-07-15	2007-01-25	Laboratorios Del Dr. Esteve, S.A.	(rac)-n-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydr0-1h-pyrazole-3-carboxamide hydrates
WO2007009720A2 (en) *	2005-07-15	2007-01-25	Laboratorios Del Dr. Esteve S.A.	Prodrugs of pyrazoline compounds, their preparation and use as medicaments
EP1749820A1 (de) *	2005-07-15	2007-02-07	Laboratorios Del Dr. Esteve, S.A.	Salze von substituierten Pyrazolin Derivaten, ihre Herstellung und Anwendung als Arzneimittel
WO2007009682A1 (en) *	2005-07-15	2007-01-25	Laboratorios Del Dr. Esteve, S.A.	Oral pharmaceutical formulations comprising substituted pyrazoline compounds
ES2337005B1 (es) *	2005-07-15	2011-01-10	Laboratorios Del Dr. Esteve, S.A.	Compuestos de pirazolina azepan o azocansustituidos, su preparacion ysu uso como medicamentos.
EP1757588A1 (de) *	2005-07-29	2007-02-28	Laboratorios Del Dr. Esteve, S.A.	Polymorph des N-Piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxamids und seine Verwendung als Cannabinoid-Rezeptor-Modulator
EP1743642A1 (de) *	2005-07-15	2007-01-17	Laboratorios Del Dr. Esteve, S.A.	Verwendung substituierter Pyrazolinverbindungen und ihrer Derivate zur Behandlung von Cannabinoidsystem-assoziierten Erkrankungen.
EP1849784A1 (de) *	2006-04-26	2007-10-31	Laboratorios Del Dr. Esteve, S.A.	Indolin-substituierte Pyrazolinderivate, ihre Herstellung und Anwendung als Arzneimittel
WO2007009687A1 (en) *	2005-07-15	2007-01-25	Laboratorios Del Dr. Esteve, S.A.	Carbonyl substituted pyrazoline compounds, their preparation and use as cb1 receptor modulators
ES2327379B1 (es) *	2005-07-15	2010-05-28	Laboratorios Del Dr. Esteve, S.A.	Compuestos de pirazolina indolinsustituidos, su preparacion y su uso como medicamentos.
EP1743892A1 (de) *	2005-07-15	2007-01-17	Laboratorios del Dr. Esteve S.A.	Substituierte Pyrazolin Verbindungen, deren Herstellung und Verwendung als Medikament
EP1849776A1 (de) *	2006-04-26	2007-10-31	Laboratorios Del Dr. Esteve, S.A.	Azepan- oder Azocan-substituierte Pyrazolinderivate, deren Herstellung und Anwendung als Arzneimittel
EP1749819A1 (de) *	2005-07-15	2007-02-07	Laboratorios Del Dr. Esteve, S.A.	(rac)-N-piperidinyl-5-(4-chlorphenyl)-1(2,4-dichlorphenyl)-4,5-dihydro-1H-pyrazol-3-carboxamid Hydraten
EP1743888A1 (de) *	2005-07-15	2007-01-17	Laboratorios Del Dr. Esteve, S.A.	Carbonyl-substituierte Pyrazolin-Verbindungen zur Verwendung als CB1-Rezeptor Modulatoren
EP1745783A1 (de) *	2005-07-15	2007-01-24	Laboratorios del Dr. Esteve S.A.	Substituierte Pyrazolinverbindungen, ihre Synthese und ihre Verwendung als Medikamente
WO2007009699A2 (en) *	2005-07-15	2007-01-25	Laboratorios Del Dr. Esteve, S.A	Use of substituted pyrazoline compounds and their derivatives for the treatment of cannabinoid system-associated diseases
ES2326461B1 (es) *	2005-07-15	2010-04-19	Laboratorios Del Dr. Esteve, S.A.	Polimorfo de n-priperidinil-5-(4-clorofenil)-1-(2,4-dicloforenil)-4,5-dihidro-1h-pirazol-3-carboxamida y su uso como modulador de receptores de cannabinoides.
WO2007009690A1 (en) *	2005-07-15	2007-01-25	Laboratorios Del Dr. Esteve, S.A	Heterocyclyl-substituted pyrazoline compounds, their preparation and use as medicaments
EP1743890A1 (de) *	2005-07-15	2007-01-17	Laboratorios Del Dr. Esteve, S.A.	4,5-Dihydro-1H-Pyrazol-Derivative, Verfahren zur Herstellung und ihre Verwendung als Medikamente.
EP1757589A1 (de) *	2005-07-29	2007-02-28	Laboratorios Del Dr. Esteve, S.A.	Amorphe-Phase von einem substituierten Pyrazolin, deren Herstellung und Verwendung als Medikament
ES2326357B1 (es) *	2005-07-29	2010-04-21	Laboratorios Del Dr. Esteve, S.A.	Fase amorfa de una pirazolina sustituida, su preparacion y su uso como medicamento.
EP1911747A1 (de)	2006-10-11	2008-04-16	Laboratorios del Dr. Esteve S.A.	Sulfonamid-substituierte Pyrazolin-derivate, deren Herstellung sowie deren Verwendung als CB1 Modulatoren
ES2330071B1 (es) *	2007-01-15	2010-07-05	Laboratorios Del Dr. Esteve, S.A.	Combinacion de sustancias activas.
EP1944295A1 (de) *	2007-01-15	2008-07-16	Laboratorios del Dr. Esteve S.A.	Nicht racemische Verbindungen von (R)-N-piperidinyl-5-(4-chlorophenyl)1-1(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-3-carboxamid und (S)-N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-3-carboxamid
EP1946778A1 (de) *	2007-01-16	2008-07-23	Laboratorios del Dr. Esteve S.A.	Wirkstoffzusammensetzung für Diabetesbehandlung
EP1946777A1 (de) *	2007-01-16	2008-07-23	Laboratorios del Dr. Esteve S.A.	Substituierte Pyrazolinderivate zur Vermeidung von Gewichtszunahme
ES2328653B1 (es) *	2007-01-15	2010-05-28	Laboratorios Del Dr. Esteve S.A.	Combinacion de sustancias activas para el tratamiento de la diabetes.
EP1946779A1 (de) *	2007-01-16	2008-07-23	Laboratorios del Dr. Esteve S.A.	Zusammensetzung enthaltend substituierte Pyrazoline und gegen Dyslipämie wirksame Mittel
EP1947089A1 (de) *	2007-01-18	2008-07-23	Laboratorios del Dr. Esteve S.A.	A-Polymorph eines substituierten Pyrazolins, seine Herstellung und Verwendung als Medikament
WO2008152086A2 (en) *	2007-06-15	2008-12-18	Solvay Pharmaceuticals B.V.	4,5-dihydro-(1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators
US8410135B2 (en)	2007-06-15	2013-04-02	Solvay Pharmaceuticals B.V.	4,5 dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators
AU2008300631A1 (en)	2007-09-20	2009-03-26	Abbott Healthcare Products B.V.	5-aryl-4,5-dihydro-(1H)-pyrazoles as cannabinoid CB1
EP2042175A1 (de) *	2007-09-21	2009-04-01	Laboratorios del Dr. Esteve S.A.	Dosierungsschemata von CB1-Rezeptor-Liganden für die Behandlung von Fettleibigkeit
TW200948798A (en) *	2008-04-23	2009-12-01	Solvay Pharm Bv	(5R)-1, 5-diaryl-4, 5-dihydro-1H-pyrazole-3-carboxamidine derivatives having CB1-antagonistic activity
US11155521B2 (en)	2012-11-13	2021-10-26	The United States Of America As Represented By The Secretary, Department Of Health And Human Services	Cannabinoid receptor mediating compounds
CA2889697C (en)	2012-11-13	2023-03-14	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Cannabinoid receptor mediating compounds
WO2014208939A1 (en) *	2013-06-28	2014-12-31	Hanmi Pharm. Co., Ltd.	1,5-diaryl-4,5-dihydro-1h-pyrazole-3-carboxamidine derivatives as cannabinoid cb1 receptor antagonist, method for preparing same, and pharmaceutical composition comprising same
CN106660968B (zh) *	2014-05-09	2020-02-07	美国政府(由卫生和人类服务部的部长所代表)	吡唑衍生物及其作为大麻素受体介体的用途
CN115536649B (zh) *	2022-10-27	2024-12-20	成都中医药大学	一种多取代吡唑啉类化合物及其合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE57690T1 (de) *	1987-01-05	1990-11-15	Du Pont	Pyrazolin mit insektizidischer aktivitaet.
WO1992003421A2 (en) *	1990-08-17	1992-03-05	E.I. Du Pont De Nemours And Company	Arthropodicidal pyrazolines, pyrazolidines and hydrazines
JPH07504658A (ja) *	1992-03-02	1995-05-25	イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー	殺節足動物性アミド類
FR2713225B1 (fr) *	1993-12-02	1996-03-01	Sanofi Sa	N-pipéridino-3-pyrazolecarboxamide substitué.
JP2004500401A (ja) *	2000-03-23	2004-01-08	ソルベイ・フアーマシユーチカルズ・ベー・ブイ	Ｃｂ１−拮抗活性を有する４，５−ジヒドロ−１ｈ−ピラゾール誘導体
ATE284872T1 (de) *	2001-03-22	2005-01-15	Solvay Pharm Bv	4,5-dihydro-1h-pyrazolderivate mit cb1- antagonistischer wirkung
ES2272809T3 (es) *	2001-09-21	2007-05-01	Solvay Pharm Bv	Nuevos derivados de 4,5-dihidro-1h-pirazol con actividad antagonista de cb1.
US6974810B2 (en) *	2001-09-21	2005-12-13	Solvay Pharmaceuticals B.V.	4,5-Dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activity

2005
- 2005-01-27 AT AT05707857T patent/ATE402697T1/de active
- 2005-01-27 CN CNB2005800034967A patent/CN100563651C/zh not_active Expired - Fee Related
- 2005-01-27 PT PT05707857T patent/PT1713475E/pt unknown
- 2005-01-27 BR BRPI0507005-8A patent/BRPI0507005A/pt not_active IP Right Cessation
- 2005-01-27 AU AU2005210163A patent/AU2005210163B2/en not_active Ceased
- 2005-01-27 DE DE602005008555T patent/DE602005008555D1/de not_active Expired - Lifetime
- 2005-01-27 SI SI200530419T patent/SI1713475T1/sl unknown
- 2005-01-27 PL PL05707857T patent/PL1713475T3/pl unknown
- 2005-01-27 JP JP2006550185A patent/JP4693787B2/ja not_active Expired - Fee Related
- 2005-01-27 CA CA002552940A patent/CA2552940A1/en not_active Abandoned
- 2005-01-27 HR HR20080549T patent/HRP20080549T3/xx unknown
- 2005-01-27 MX MXPA06008593A patent/MXPA06008593A/es active IP Right Grant
- 2005-01-27 DK DK05707857T patent/DK1713475T3/da active
- 2005-01-27 ES ES05707857T patent/ES2311972T3/es not_active Expired - Lifetime
- 2005-01-27 WO PCT/EP2005/050339 patent/WO2005074920A1/en not_active Ceased
- 2005-01-27 EP EP05707857A patent/EP1713475B1/de not_active Expired - Lifetime
- 2005-01-27 RU RU2006131132/04A patent/RU2360904C2/ru not_active IP Right Cessation
- 2005-01-27 KR KR1020067017475A patent/KR20060131861A/ko not_active Ceased
2006
- 2006-06-26 IL IL176547A patent/IL176547A/en not_active IP Right Cessation
- 2006-08-30 NO NO20063866A patent/NO20063866L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
JP4693787B2 (ja)	2011-06-01
PL1713475T3 (pl)	2009-03-31
AU2005210163A1 (en)	2005-08-18
HRP20080549T3 (en)	2008-11-30
JP2007519686A (ja)	2007-07-19
RU2006131132A (ru)	2008-03-10
PT1713475E (pt)	2008-11-10
CA2552940A1 (en)	2005-08-18
WO2005074920A1 (en)	2005-08-18
ES2311972T3 (es)	2009-02-16
IL176547A0 (en)	2006-10-31
HK1099688A1 (en)	2007-08-24
AU2005210163B2 (en)	2010-05-13
MXPA06008593A (es)	2006-08-28
BRPI0507005A (pt)	2007-06-05
SI1713475T1 (sl)	2008-12-31
NO20063866L (no)	2006-10-27
CN1913885A (zh)	2007-02-14
CN100563651C (zh)	2009-12-02
IL176547A (en)	2010-06-30
KR20060131861A (ko)	2006-12-20
EP1713475A1 (de)	2006-10-25
EP1713475B1 (de)	2008-07-30
RU2360904C2 (ru)	2009-07-10
DK1713475T3 (da)	2008-12-01
DE602005008555D1 (de)	2008-09-11

Legal Events

Date

Code

Title

Description

2009-01-15

UEP

Publication of translation of european patent specification

Ref document number: 1713475

Country of ref document: EP

Publication	Publication Date	Title
DE602005008555D1 (de)	2008-09-11	1,3,5-trisubstituierte 4,5-dihydro-1h-pyrazol-derivative mit cb1-antagonistischer aktivität
WO2009016460A3 (en)	2009-03-26	Pyrazole compounds and their use as raf inhibitors
MY148703A (en)	2013-05-31	Polycyclic cinnamide derivatives
MY143565A (en)	2011-05-31	Novel fluorocglycoside derivatives of pyrazoles: medicaments containing these compounds, and the use thereof
WO2007020502A3 (en)	2007-04-19	Cannabinoid receptor ligands and uses thereof
DE602005007350D1 (de)	2008-07-17	Pyridin-4-yl-ethynylimidazole und -pyrazole als antagonisten des mglu5-rezeptors
WO2008108378A3 (en)	2008-12-04	Bicyclic oxomorpholine derivative
TW200716135A (en)	2007-05-01	Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
GEP20125637B (en)	2012-09-10	Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them
CY1117851T1 (el)	2017-05-17	Παραγωγα φαινυλ-πυρρολ-αμινογουανιδινης
DE602004011394D1 (en)	2008-03-06	Thiazolderivate
WO2005060959A8 (en)	2006-01-12	Pyrazole derivatives and use thereof as orexin receptor antagonists
WO2010056644A8 (en)	2010-11-18	1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
ATE411296T1 (de)	2008-10-15	Imidazolinderivate mit cb1-antagonistischer wirkung
NO20070089L (no)	2007-01-05	DPP-IV inhibitorer
TNSN07006A1 (en)	2008-06-02	Novel heterocyclic compounds
WO2005075450A3 (en)	2006-03-30	Spiro-benzodioxoles and their use as cb1 antagonists
UA100862C2 (ru)	2013-02-11	Шестичленные ароматические соединения, их получение и применение (варианты)
TW200714603A (en)	2007-04-16	Acylaminobicyclic heteroaromatic compounds and uses thereof
DE502005008351D1 (de)	2009-11-26	Chinolinderivat, dessen verwendung, herstellung und dieses enthaltendes arzneimittel
EA200870074A1 (ru)	2008-12-30	Производные 4,5-дигидро-(1н)-пиразола в качестве модуляторов каннабиноидного рецептора св1
UA84594C2 (en)	2008-11-10	1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives as cb1 antagonists
NO20052197L (no)	2005-05-04	Fremgangsmate for fremstilling av pyrazol
EA201070381A1 (ru)	2010-12-30	5-арил-4,5-дигидро-(1н)-пиразолы в качестве агонистов каннабиоидного сврецептора
MY145008A (en)	2011-12-15	1-arylpyrazole derivatives as pesticidal agents